Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

A. Ghezzi; L. M E Grimaldi; M. G. Marrosu; C. Pozzilli; G. Comi; A. Bertolotto; M. Trojano; P. Gallo; R. Capra; D. Centonze; E. Millefiorini; S. Sotgiu; V. Brescia Morra; M. P. Amato; A. Lugaresi; G. Mancardi; D. Caputo; E. Montanari; L. Provinciali; L. Durelli; R. Bergamaschi; P. Bellantonio; M. R. Tola; S. Cottone; G. Savettieri; G. Tedeschi

doi:10.1007/s10072-010-0469-0

Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

A. Ghezzi, L. M E Grimaldi, M. G. Marrosu, C. Pozzilli, G. Comi, A. Bertolotto, M. Trojano, P. Gallo, R. Capra, D. Centonze, E. Millefiorini, S. Sotgiu, V. Brescia Morra, M. P. Amato, A. Lugaresi, G. Mancardi, D. Caputo, E. Montanari, L. Provinciali, L. DurelliR. Bergamaschi, P. Bellantonio, M. R. Tola, S. Cottone, G. Savettieri, G. Tedeschi

Research output: Contribution to journal › Article › peer-review

Abstract

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

Original language	English
Pages (from-to)	351-358
Number of pages	8
Journal	Neurological Sciences
Volume	32
Issue number	2
DOIs	https://doi.org/10.1007/s10072-010-0469-0
Publication status	Published - Apr 2011

Keywords

IRIS
Multiple sclerosis
Natalizumab
PML

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Dermatology

Access to Document

10.1007/s10072-010-0469-0

Cite this

Ghezzi, A., Grimaldi, L. M. E., Marrosu, M. G., Pozzilli, C., Comi, G., Bertolotto, A., Trojano, M., Gallo, P., Capra, R., Centonze, D., Millefiorini, E., Sotgiu, S., Brescia Morra, V., Amato, M. P., Lugaresi, A., Mancardi, G., Caputo, D., Montanari, E., Provinciali, L., ... Tedeschi, G. (2011). Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society. Neurological Sciences, 32(2), 351-358. https://doi.org/10.1007/s10072-010-0469-0

Ghezzi, A, Grimaldi, LME, Marrosu, MG, Pozzilli, C, Comi, G, Bertolotto, A, Trojano, M, Gallo, P, Capra, R, Centonze, D, Millefiorini, E, Sotgiu, S, Brescia Morra, V, Amato, MP, Lugaresi, A, Mancardi, G, Caputo, D, Montanari, E, Provinciali, L, Durelli, L, Bergamaschi, R , Bellantonio, P, Tola, MR, Cottone, S, Savettieri, G & Tedeschi, G 2011, 'Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society', Neurological Sciences, vol. 32, no. 2, pp. 351-358. https://doi.org/10.1007/s10072-010-0469-0

@article{7b33e08560094efe81d6731c7a01f238,

title = "Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society",

abstract = "Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.",

keywords = "IRIS, Multiple sclerosis, Natalizumab, PML",

author = "A. Ghezzi and Grimaldi, {L. M E} and Marrosu, {M. G.} and C. Pozzilli and G. Comi and A. Bertolotto and M. Trojano and P. Gallo and R. Capra and D. Centonze and E. Millefiorini and S. Sotgiu and {Brescia Morra}, V. and Amato, {M. P.} and A. Lugaresi and G. Mancardi and D. Caputo and E. Montanari and L. Provinciali and L. Durelli and R. Bergamaschi and P. Bellantonio and Tola, {M. R.} and S. Cottone and G. Savettieri and G. Tedeschi",

year = "2011",

month = apr,

doi = "10.1007/s10072-010-0469-0",

language = "English",

volume = "32",

pages = "351--358",

journal = "Neurological Sciences",

issn = "1590-1874",

publisher = "Springer-Verlag Italia s.r.l.",

number = "2",

}

TY - JOUR

T1 - Natalizumab therapy of multiple sclerosis

T2 - Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

AU - Ghezzi, A.

AU - Grimaldi, L. M E

AU - Marrosu, M. G.

AU - Pozzilli, C.

AU - Comi, G.

AU - Bertolotto, A.

AU - Trojano, M.

AU - Gallo, P.

AU - Capra, R.

AU - Centonze, D.

AU - Millefiorini, E.

AU - Sotgiu, S.

AU - Brescia Morra, V.

AU - Amato, M. P.

AU - Lugaresi, A.

AU - Mancardi, G.

AU - Caputo, D.

AU - Montanari, E.

AU - Provinciali, L.

AU - Durelli, L.

AU - Bergamaschi, R.

AU - Bellantonio, P.

AU - Tola, M. R.

AU - Cottone, S.

AU - Savettieri, G.

AU - Tedeschi, G.

PY - 2011/4

Y1 - 2011/4

N2 - Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

AB - Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

KW - IRIS

KW - Multiple sclerosis

KW - Natalizumab

KW - PML

UR - http://www.scopus.com/inward/record.url?scp=79952902537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952902537&partnerID=8YFLogxK

U2 - 10.1007/s10072-010-0469-0

DO - 10.1007/s10072-010-0469-0

M3 - Article

C2 - 21234775

AN - SCOPUS:79952902537

VL - 32

SP - 351

EP - 358

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 2

ER -

Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this